newsfilter
← Latest News
GlobeNewswire·

IRulya Therapeutics to Participate in the Craig-Hallum Biotech Catalyst Conference

  • IRulya Therapeutics Inc. (NASDAQ: IRLA) senior management will participate in a Fireside Chat at the Craig-Hallum Biotech Catalyst Conference on Thursday, October 22, 2026.
  • A replay of the webcast will be available on the company's investor website following the event & archived for at least 30 days.
  • The company is developing LAM-001 for pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post lung transplant (BOS), & sarcoidosis associated pulmonary hypertension (SAPH).
  • A Phase 2a clinical study for PH patients has been completed.
  • A Phase 2 clinical study in BOS patients is ongoing.
  • A Phase 2b clinical study in PH-ILD patients is ongoing.
  • A Phase 2 clinical study in SAPH is anticipated to begin in the fourth quarter of 2026.
  • The company anticipates its cash runway will fund operations through the end of 2028.
  • Forward-looking statements regarding development timelines, regulatory processes, & potential benefits are subject to risks & uncertainties detailed in the release & the company's Form 10-Q filed on August 14, 2026.